According to immunofluorescence and quantitative PCR studies, concurrent treatment with the ETA/B receptors antagonist (bosentan) blocked CH-induced macrophage invasion and the upregulation of pro-inflammatory cytokines and monocyte chemoattractant protein-1 (MCP-1). Here, CCL2 is linked to cyclic hematopoiesis.